Refsum Disease
Introduction
Refsum Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Refsum disease, also known as heredopathia atactica polyneuritiformis, is a rare autosomal recessive peroxisomal disorder characterized by a accumulation of phytanic acid in tissues and plasma due to impaired fatty acid oxidation. This leads to a progressive neurodegenerative syndrome featuring retinitis pigmentosa, peripheral neuropathy, cerebellar ataxia, and hearing loss.[@unique] [@electrodiagnostic]
Overview
Refsum disease was first described by Sigvald Refsum in 1946 as a familial syndrome combining retinitis pigmentosa, peripheral neuropathy, ataxia, and elevated cerebrospinal fluid protein. It is classified as a peroxisomal biogenesis disorder and represents one of the few treatable causes of hereditary ataxia, as dietary phytanic acid restriction can significantly alter the disease course.[@electrodiagnostic] [@zellweger]
The disease is rare, with an estimated prevalence of 1 in 1,000,000 individuals worldwide. However, certain populations show higher frequencies due to founder mutations, particularly in Norway and other Scandinavian countries.[@zellweger] [@refsum]
Genetics
Gene Defect
...Refsum Disease
Introduction
Refsum Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Refsum disease, also known as heredopathia atactica polyneuritiformis, is a rare autosomal recessive peroxisomal disorder characterized by a accumulation of phytanic acid in tissues and plasma due to impaired fatty acid oxidation. This leads to a progressive neurodegenerative syndrome featuring retinitis pigmentosa, peripheral neuropathy, cerebellar ataxia, and hearing loss.[@unique] [@electrodiagnostic]
Overview
Refsum disease was first described by Sigvald Refsum in 1946 as a familial syndrome combining retinitis pigmentosa, peripheral neuropathy, ataxia, and elevated cerebrospinal fluid protein. It is classified as a peroxisomal biogenesis disorder and represents one of the few treatable causes of hereditary ataxia, as dietary phytanic acid restriction can significantly alter the disease course.[@electrodiagnostic] [@zellweger]
The disease is rare, with an estimated prevalence of 1 in 1,000,000 individuals worldwide. However, certain populations show higher frequencies due to founder mutations, particularly in Norway and other Scandinavian countries.[@zellweger] [@refsum]
Genetics
Gene Defect
Refsum disease is caused by homozygous or compound heterozygous mutations in the PAHX gene (peroxisomal 2-hydroxyacyl-CoA lyase), located on chromosome 10p13. This gene encodes the enzyme phytanoyl-CoA hydroxylase, which is essential for the peroxisomal oxidation of phytanic acid, a branched-chain fatty acid derived from dietary sources.[@refsum] [@synthesis]
More recently, mutations in the PEX7 gene (peroxisome biogenesis factor 7) have been identified in some patients with Refsum disease phenotypes, particularly those with additional features like rhizomelic chondrodysplasia punctata.[@synthesis] [^6]
Inheritance Pattern
- Pattern: Autosomal recessive
- Carrier frequency: Approximately 1 in 200 in general population
- Risk to siblings of affected individuals: 25%
Pathophysiology
Phytanic acid (3,7,11,15-tetramethylhexadecanoic acid) is a branched-chain fatty acid found primarily in dairy products, ruminant fats, and some fish oils. Normal metabolism occurs via: [^7]
Peroxisomal β-oxidation: Phytanoyl-CoA is converted to pristanic acid by phytanoyl-CoA hydroxylase (PAHX)
Further processing: Pristanic acid undergoes additional peroxisomal and mitochondrial oxidation
Energy production: The resulting products enter mitochondrial β-oxidationBiochemical Consequences
In Refsum disease, the deficient enzyme causes: [^8]
- Phytanic acid accumulation: Levels can reach 10-50 times normal (normal: < 30 μmol/L; patients: 300-3000 μmol/L)
- Membrane incorporation: Phytanic acid incorporates into neuronal and retinal cell membranes
- Oxidative stress: Accumulated phytanic acid promotes [reactive oxygen species](/entities/reactive-oxygen-species) generation
- Myelin dysfunction: Altered membrane properties affect nerve conduction<br>[^6]
Clinical Features
Classic Tetrad
The traditional presentation includes four cardinal features: [^9]
| Feature | Description | Frequency |
|---------|-------------|----------|
| Retinitis pigmentosa | Progressive vision loss, tunnel vision, nyctalopia (night blindness) | 100% |
| Peripheral neuropathy | Motor and sensory neuropathy, distal weakness, reduced reflexes | 95% |
| Cerebellar ataxia | Gait instability, dysmetria, dysarthria | 90% |
| Sensorineural hearing loss | Progressive hearing impairment | 85% |
Additional Manifestations
- Anosmia (loss of smell): Often an early sign
- Ichthyosis (dry, scaly skin): Present in approximately 40%
- Cardiac conduction abnormalities: Including bundle branch block
- Mild cognitive impairment: In some patients
- Skeletal abnormalities: Including epiphyseal dysplasia
- Cryptorchidism (undescended testicles): In male patients<br>[^7]
Age of Onset
- Typical onset: Second to fourth decade
- Range: 5-50 years
- Retinitis pigmentosa: Usually first manifestation
- Neurological symptoms: Develop 5-10 years after ocular symptoms
Disease Progression
Without treatment:
Stage 1 (ages 5-20): Visual problems, night blindness
Stage 2 (ages 15-30): Onset of neurological symptoms - ataxia, neuropathy
Stage 3 (ages 25-50): Progressive disability, hearing loss
Stage 4 (ages 40-60): Severe disability, possible premature deathWith treatment, progression can be significantly slowed or halted.<br>[^8]
Diagnosis
Diagnostic Criteria
Clinical triad: Retinitis pigmentosa + peripheral neuropathy + ataxia (or hearing loss)
Elevated phytanic acid: Plasma levels > 100 μmol/L
Genetic confirmation: Biallelic pathogenic variants in PAHX or PEX7
Normal very-long-chain fatty acids: Distinguishes from Zellweger spectrumLaboratory Findings
| Test | Finding |
|------|--------|
| Plasma phytanic acid | Markedly elevated (100-3000 μmol/L) |
| Plasma pristanic acid | Normal or mildly elevated |
| Very-long-chain fatty acids | Normal |
| Pipecolic acid | Normal |
| Red blood cell plasmalogens | Normal |
| CSF protein | Elevated in 60% |
Imaging and Electrophysiology
- MRI brain: May show cerebellar atrophy in advanced cases
- Nerve conduction studies: Axonal sensory-motor neuropathy
- EEG: Usually normal
- ECG: May show conduction abnormalities
Treatment
Dietary Management
Phytanic acid restriction is the cornerstone of treatment:
| Food to Avoid | Alternatives |
|--------------|-------------|
| Dairy products (milk, cheese, butter) | Dairy-free alternatives |
| Ruminant meat (beef, lamb, goat) | Poultry, fish |
| Animal fats | Vegetable oils (except palm) |
| Certain fish (herring, mackerel) | Cod, haddock |
| Foods containing phytol | Avoid green leafy vegetables (cooked) |
Plasmalogen Supplementation
- Emerging therapy: Docosahexaenoic acid (DHA) supplementation
- Rationale: May support membrane function in the absence of phytanic acid metabolism
Symptomatic Treatments
- Hearing aids for hearing loss
- Low-vision aids for retinitis pigmentosa
- Physical therapy for ataxia and neuropathy
- Cardiac monitoring for conduction abnormalities
- Vitamin A and E supplementation (some benefit reported)
Monitoring
- Plasma phytanic acid levels: Every 3-6 months
- Neurological examination: Annually
- Ophthalmological evaluation: Annually
- Audiometry: Annually
- ECG: Annually
Prognosis
With early diagnosis and strict dietary management:
- Vision loss: Can be stabilized
- Neurological progression: Often halted or slowed significantly
- Life expectancy: Normal or near-normal with treatment
- Quality of life: Substantially improved
Without treatment:
- Progressive neurodegeneration leading to severe disability
- Median survival: 40-50 years after symptom onset<br>[^9]
Differential Diagnosis
| Condition | Key Distinguishing Features |
|-----------|---------------------------|
| Usher syndrome | Retinitis pigmentosa + hearing loss, but no ataxia or elevated phytanic acid |
| Friedreich's ataxia | Ataxia + neuropathy + cardiomyopathy, but no retinitis pigmentosa |
| Ataxia with vitamin E deficiency | Low vitamin E, different pattern of neurological involvement |
| Other peroxisomal disorders | Elevated VLCFA in Zellweger spectrum |
| Charcot-Marie-Tooth disease | Neuropathy without retinitis pigmentosa |
See Also
- [Peroxisomes](/entities/peroxisomes) - Cellular organelles involved in fatty acid metabolism
- [Retinitis Pigmentosa](/diseases/retinitis-pigmentosa) - Progressive retinal degeneration
- [Friedreich's Ataxia](/diseases/friedreichs-ataxia) - Another hereditary ataxia
- [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia) - Group of ataxic disorders
External Links
- [National Institute of Neurological Disorders and Stroke (NINDS)](https://www.ninds.nih.gov)
- [National Ataxia Foundation](https://ataxia.org)
- [Retina International](https://retina-international.org)
- [OMIM: Refsum Disease](https://www.omim.org/entry/266500)
- [GeneReviews: Refsum Disease](https://www.ncbi.nlm.nih.gov/books/NBK1353/)
Background
The study of Refsum Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent Research (2024-2026)
This section highlights recent publications relevant to this disease.
- [A unique case of microspherophakia in adult Refsum disease.](https://pubmed.ncbi.nlm.nih.gov/41487288/) (2026 Mar) - American journal of ophthalmology case reports
- [Electrodiagnostic Evaluation of Peripheral Neuropathy.](https://pubmed.ncbi.nlm.nih.gov/33085316/) (2026 Jan) -
- [Zellweger Spectrum Disorder.](https://pubmed.ncbi.nlm.nih.gov/32809511/) (2026 Jan) -
- [Refsum Disease.](https://pubmed.ncbi.nlm.nih.gov/32809453/) (2026 Jan) -
- [Synthesis of stable isotope labeled analogs of phytanic acid for separate and combined tracing of alpha-, beta- and omega-oxidation.](https://pubmed.ncbi.nlm.nih.gov/41394623/) (2025 Nov 27) - bioRxiv : the preprint server for biology
References